

Berberis integerrima ameliorates insulin resistance in high-fructose-fed insulin-resistant rats

Hossein Fallah¹, Hamed Akbari^{2, 3}, Moslem Abolhassani³, Abbas Mohammadi^{1*}, Ahmad Gholamhosseinian¹

¹ Department of Biochemistry, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran

² Endocrinology and Metabolism Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran

³ Student Research Committee, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran

ARTICLE INFO

Article type:

Original article

Article history:

Received: Jan 12, 2017

Accepted: Aug 10, 2017

Keywords:

Adiponectin
Diabetes
Free fatty acids
Insulin resistance
Metabolic syndrome

ABSTRACT

Objective(s): This study was aimed to investigate the effect of *Berberis integerrima* (*B. integerrima*) extract on insulin sensitivity in high-fructose-fed insulin-resistant rats.

Materials and Methods: Experimental rats were randomly divided into two groups: the control group was fed a regular chow diet while other group fed with a high-fructose diet for 8 weeks. After the first six weeks, the animals were treated with *B. integerrima* extract or pioglitazone for two weeks. Insulin and adiponectin levels were measured by ELISA. Additionally, Insulin resistance was calculated using a Homeostasis Model Assessment of Insulin resistance (HOMA-IR). The plasma free fatty acid (FFA) profile was obtained by gas chromatography. PPAR γ and GLUT4 gene expression were assessed by real-time polymerase chain reaction (PCR) and western-blotting.

Results: Comparing the *B. integerrima* treated group with the control group, weight gain ($P=0.009$) and levels of insulin ($P=0.001$), blood glucose ($P<0.0001$), and HOMA-IR ($P<0.0001$) were significantly reduced. Additionally, the adiponectin concentration was significantly increased ($P<0.0001$). Among the FFA fractions, the mean concentration of palmitoleic acid and stearic acid in the *B. integerrima* group were significantly higher than the control group ($P<0.0001$ and $P=0.005$, respectively). However, there was no significant difference at the mRNA and protein level of GLUT4 and PPAR- γ between *B. integerrima* treated group and control group.

Conclusion: The study findings revealed that *B. integerrima* might be a protective candidate against Type 2 diabetes/insulin resistance through direct insulin-like effect and an increase in adiponectin levels. However, the mechanism of *B. integerrima* was independent of GLUT4 and PPAR γ .

► Please cite this article as:

Fallah H, Akbari H, Abolhassani M, Mohammadi A, Gholamhosseinian A. *Berberis integerrima* ameliorates insulin resistance in high-fructose-fed insulin-resistant rats. Iran J Basic Med Sci 2017; 20:1093-1101. doi: 10.22038/IJBMS.2017.9409

Introduction

Obesity is the primary disease of adipocytes and is strongly associated with serious comorbidities that impair an individual's health (1, 2). Obesity is closely related to insulin resistance and other chronic diseases including all components of metabolic syndrome, cardiovascular diseases, type 2 diabetes mellitus (T2DM), and certain types of cancers (2–4). Chronic consumption of high-fat diets leading to the development of obesity can induce insulin resistance in both human and animals (5).

Insulin resistance is defined as impaired ability of insulin to promote glucose uptake and exert its metabolic effects in its target tissues (liver, skeletal muscle and adipose tissue) (6, 7). Moreover, intensive studies have demonstrated a strong association between obesity and insulin resistance with dysregulation of adipokines (8–10). Adiponectin, one of the most abundant adipokines secreted exclusively

by adipocytes, plays an influential effect in insulin-sensitizing and anti-diabetic activity (8–12). Recent findings have revealed that adiponectin exerts its effect by binding to both AdipoR1 and AdipoR2 receptors, thereby leading to the activation of peroxisome proliferator-activated receptors (PPARs) and 5'AMP-activated protein kinase (AMPK) signaling pathways (11, 13). Subsequently, PPARs and AMPK cause an increase in fatty acid oxidation and glucose uptake (14, 15).

Several mechanisms have been proposed that increased free fatty acids (FFAs) interference with insulin function (16–19). High circulating levels of FFA not only inhibit lipolysis but also prevent insulin signaling pathway through activating protein kinases such as protein kinase C (PKC), and c-JUN NH2-terminal protein kinase (JNK) (2, 20). Since insulin acts as an effective inhibitor of lipolysis, increased circulating levels of FFAs contribute to

*Corresponding author: Abbas Mohammadi. Department of Biochemistry, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran. Fax: +98-341-3222048; email: gh_mohammadi@kmu.ac.ir

insulin resistance (17, 21).

It is well established that insulin resistance is associated with increase in inflammatory mediators such as tumor necrosis factor α (TNF- α), interleukin 6 (IL-6), IL-10, plasminogen activator inhibitor-1 (PAI-1), macrophages and monocyte chemoattractant protein-1 (MCP-1), leptin and resistin (16, 21–23). These cytokines can interfere with the binding of IRS1/2 to the insulin receptor by activating the suppressor of cytokine signaling (SOCS) proteins and several serine/threonine kinases such as JNK, PKC, and I κ B kinase β (IKK- β) (22, 24). Furthermore, an imbalance in energy metabolism of skeletal muscles plays an essential role in the development of metabolic diseases (25). The overproduction of lipids in skeletal muscles contributes to inhibition of glucose uptake through GLUT4 translocation from intracellular location to plasma membranes which can lead to insulin resistance (22, 23). In turn, regulation of GLUT4 is a major contributor of glucose metabolism in both skeletal muscle and adipose tissue (22, 23).

PPAR is a ligand-activated transcription factor which has three isotypes (α , γ , and β/δ) (26). Activation of PPAR enhances insulin resistance and promotes lipid metabolism by increasing FFA oxidation and repressing the expression of leptin gene (2, 27). Rosiglitazone and pioglitazone which are subclasses of thiazolidinedione (TZD) are recognized as PPAR- γ agonists (28). These drugs have been used clinically as regulators of genes involved in glucose, lipid, and protein metabolism to control hyperglycemic status in patients with T2DM (29,30). However, drugs like fibrates (the PPAR α agonists), and the mentioned PPAR- γ agonist cause an increase in the risk of cardiovascular disease and bladder cancer (31, 32). Consequently, much attention has been focused on functional food ingredients and herbal extracts to reduce the mortality rate and other serious side effects (1, 31).

Berberis integerrima, a plant belonging to Berberidaceae family, has exclusively been cultivated in Iran, especially in Northern and North-eastern regions where it is referred to as Zereshk in the Persian language (33–35). In traditional medicine, *B. integerrima* was mainly used as an impressive medicine for treating diabetes in the Alamut region, in the province of Qazvin, Iran (33). Furthermore, *B. integerrima* was used to treat various type of infectious fevers, diarrhea and it has also been reported to have other effects including hypolipidemic, hypotensive, and anti-inflammatory features (33, 34). Many components of *B. integerrima* have been identified. The main constituents of the plant include berberine, palmatine chloride, berberine chloride, oxyacanthine, berbamine, and columbamine, among them, berberine is the most important active constituent found in the bark of the root, stem, and unripe fruit (33–37). Pharmaceutical

and therapeutic effects of berberine have also been reported in treating diabetes. Previous studies have indicated that berberine improves insulin sensitivity and glucose uptake by activating protein kinase B and increasing glucose uptake through AMPK and AMPK-P38 pathways (36, 38).

Nevertheless, available data regarding the effects of *B. integerrima* extract on the possible mechanisms of insulin resistance are scarce. As skeletal muscles and hepatic tissue are the chief parts involved in insulin function and energy homeostasis, we selected these two tissues. In the direction of unknown mechanisms and low evidence, the objective of the present study was to examine the effects of *B. integerrima* root extract on muscle and hepatic insulin resistance in rats to determine the possible mechanisms involved.

Materials and Methods

Preparation of extract

B. integerrima was collected from Fars province, Iran. Its genus and species were approved by the department of botany, at Bahonar University, Kerman, Iran (Voucher specimen no: KF1194). After collecting the plants, fruits were dried in the shade at 30 °C. Dried fruits were milled and converted into powder. The resulting powder was extracted by maceration method (300 g in 1000 ml distilled water) for 48 hrs at room temperature (39). After filtration water was evaporated at 40 °C in an oven and dried extract was stored at -20 °C.

Experimental animals and treatment

In this experimental study, male Wistar rats (weighing 250–300 g) were obtained from the animal house of Kerman University of Medical Sciences. The Ethics Committee of Kerman University of Medical Sciences approved the study procedure. Rats were maintained in the animal room at 22±3 °C under an automatic lighting schedule (08:00–20:00 hr). They had free access to standard chow and water for two weeks. They were then randomly divided into four groups (n=8). The first three groups were fed a 60% fructose diet, whereas the fourth group, as the healthy control group (HCG) was fed with normal chow for 8 weeks (40). The fructose-enriched diet contained 60% fructose, 21% protein, and 5 % fat, sodium 0.49%, and potassium 0.49% (40). After 6 weeks, insulin resistance was confirmed by oral glucose tolerance test (OGTT).

While rats were still on the fructose diet, they were further subdivided into three groups: Two groups received an intragastric injection of *B. integerrima* extract (1000 mg/kg) (41) and pioglitazone (Sigma, Saint Louis, MO, USA) (10 mg/kg) (42) as a *B. integerrima* extract group and pioglitazone group (Pio), respectively. The third group as a control group (Con) without any treatment. These treatment

Table 1. Primers used in this study

Gene	Primers	PCR Product	Accession Number
GLUT4	F: ACTGGCGCTTTCCTGAAGT R: CGAGGCCAAGGCTAGATTTTG	106 bp	NM_012751
PPAR γ	F: CATGCTTGTGAAGGATGCAAG R: TTCTGAAACCGACAGTACTGACAT	131 bp	NM_001145367
GAPDH	F: TGGAGTCTACTGGCGTCTT R: TGTCATATTTCTCGTGGTTCA	138 bp	NM_017008

periods lasted for 2 weeks. Body weight was measured weekly throughout the study.

Blood and tissue collection

At the end of the treatment period, the food was removed for 12 hr before collecting blood samples from the heart under ether anesthesia. The blood samples were divided into two tubes with or without EDTA. Tubes were centrifuged at 6000 g for 10 min at 4 °C. Plasma (for FFA analysis) or serum (for other biochemical analyses) was immediately separated and stored at -20 °C. The hind limb skeletal muscle and liver tissue were quickly removed and then frozen in liquid nitrogen and kept at -75 °C until use.

Measurement of serum parameters

Serum concentrations of glucose, triglycerides, cholesterol, and high-density-lipoprotein-cholesterol (HDL-c) were measured by an RA-1000 autoanalyzer. Blood insulin and adiponectin levels were measured using ELISA commercial assay kits according to the manufacturer's instructions (Mouse/Rat Adiponectin or insulin ELISA kit, USCN, China). Insulin resistance was calculated using Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) equation: [(insulin (μ U/ml) \times glucose (mmol/l))/22.5].

Measurement of plasma-free fatty acids

Plasma FFAs were extracted and analyzed by the method explained by Kangani *et al.* with slight modifications (43). Five hundred microliter of plasma was mixed with 20 μ l of pentadecanoic acid (1 mg/ml) as an internal standard. Lipids were extracted from plasma by a reagent constituted from isopropanol-heptane-hydrochloric acid (1M) (40:10:1, v/v/v). After separating FFAs by TLC on silica gel plates using a heptane-ether-acetic acid [60:40:3] solvent system, FFAs were visualized by iodine vapor on TLC plates. FFA bands were scrapped, and free fatty acid methyl esters (FAME) were prepared by a reaction with BF₃ containing methanol (Sigma). Then, FFA methyl esters were separated using an Agilent GC-7890A system equipped with a flame ionization detector. The injection volume was 1 μ l in the split 30:1 injection mode. A capillary column (DB-225 20 m \times 0.1 mm I.D., 0.1 μ m film thickness, J&W GC columns, USA) was employed.

RNA extraction and real-time quantitative PCR

RNA was isolated from the skeletal muscle (for GLUT4 assay) and liver (for PPAR γ assay) tissues by RNeasy mini kit (Qiagen) according to manufacturer's instruction. The concentration of RNA was quantified by the ultraviolet (UV) light spectrophotometry at 260 nm and 280 nm (ND-1000 nanodrop). The quality of the extracted RNA was confirmed by ethidium bromide staining of 18S and 28S ribosomal RNA bands after electrophoresis on a 2% agarose gel.

Reverse transcription of RNA to cDNA was performed using Quanti Tect Reverse Transcription Kit (Qiagen) according to the manufacture's procedure. Relative Quantitative real-time PCR was conducted on a Qiagen Thermal Cycler (Rotor-Gene Q 5plex HRM System, Qiagen) using the corresponding QuantiFast SYBR Green PCR kit (Qiagen) according to manufacturer's instructions. Primer sequences used for real-time PCR are shown in Table 1. The cycle of threshold (CT) value was determined for each sample. Δ CT was calculated using the equation: Δ CT = CT (target gene) - CT (endogenous reference gene (GAPDH)). Results were calculated by the equation: $2^{-\Delta\Delta CT}$. In the real-time PCR all suggestions that published by Qiagen in "Critical Factors for Success in Real Time PCR" were considered.

Western immunoblotting analysis

Total protein was extracted from muscle or liver by homogenization in the radioimmune precipitation assay (RIPA) buffer (Sigma, cat number: R0278), followed by centrifugation at 14,000 rpm for 20 min and then supernatant containing proteins was collected. Total protein was measured by a Bradford protein assay using bovine serum albumin (BSA) as standard. Proteins were separated by using SDS- polyacrylamide gel electrophoresis and transferred on polyvinylidene difluoride (PVDF) membrane. Non-specific binding sites were blocked by overnight incubating with 5 % (w/v) non-fat skim milk in Tris-buffered saline containing 0.1% Tween 20 (TBS-T) buffer at 4 °C. Then, the membrane was washed with TBST three times (each time for 20 min) and incubated with appropriate polyclonal primary antibodies for PPAR γ (ab27649, mouse polyclonal to PPAR gamma, Abcam, UK) or GLUT4 (ab33780, mouse polyclonal to GLUT4, Abcam, UK) antibody in TBS-T buffer for 1 hr. After washing, as mentioned above, membranes were incubated with the anti-rabbit secondary antibody (Goat Polyclonal HRP




Figure 1. Effect of *Berberis integerrima* on mRNA level of liver PPAR γ and muscle GLUT4 gene expression. The chart demonstrates that *B. integerrima* did not have any effect on PPAR γ and GLUT4 gene expression at mRNA level ($P=0.928$ and $P=0.995$, respectively). However, pioglitazone significantly increased the mRNA level of PPAR γ (Figure 1). All data are expressed as mean \pm SEM. HCG: healthy control group, Con: control, Pio: pioglitazone, BIE: *Berberis integerrima* extract

conjugated antibody to rabbit IgG, ab6112, Abcam, UK), for 1 hr at room temperature. Then PVDF was washed and incubated with substrate (Western lightening plus ECL, Perkin-Elmer) for 1 min. After exposing PVDF membrane to Hyblot film (Denville) for 30 secs, in a dark room, band intensities were quantified by image j software.

Statistical analysis

All data are presented as mean \pm SEM (standard errors of the mean). The differences among groups were analyzed using one-way analysis of variance (ANOVA), and *Post-hoc* Tukey test was used to compare means between groups. The statistical analyses were performed using the SPSS software version 18.0 for Windows (SPSS Inc, Chicago, IL). $P<0.05$ were considered statistically significant.

Results

Weight gain, water and food intake

No significant difference was found among the groups in comparison of body weights at the beginning of treatment. A significant difference was observed in the body weight gain between *B. integerrima* and control groups ($P=0.009$). The difference between the initial body weight and body weight at the end of the 8th week were considered as body weight gain. *B. integerrima* reduced weight as compared to pioglitazone. However, no significant difference was observed in water or food intake between *B. integerrima* and controls groups (Table 2).

Table 2. Effect of *Berberis integerrima* on body weight, water, and food intake and other insulin resistance related parameters

Parameters	Groups				P-value*
	HCG	Con	Pio	BIE	
Initial weight (g)	275 \pm 8	272 \pm 9	272 \pm 12	255 \pm 11	0.676
Weight after 8 weeks (g)	285 \pm 9	307 \pm 8	294 \pm 16	278 \pm 15	0.421
Weight gain (g)	10 \pm 2*	35 \pm 2#	22 \pm 5	14 \pm 6*	0.009
Water intake (ml)	35 \pm 0.8*	47 \pm 2#	60 \pm 2*#	45 \pm 1#	0.749
Food intake (g)	21.6 \pm 0.7*	13.4 \pm 0.4#	13.5 \pm 0.3#	13 \pm 0.2#	0.84
Insulin (pmol/l)	50 \pm 4.8*	137 \pm 34#	40 \pm 2.7*	25 \pm 6*	0.001
Adiponectin (μ g/ml)	2.9 \pm 0.16	3.9 \pm 0.15#	5.6 \pm 0.4*#	6 \pm 0.3*#	0.000
Glucose (mg/dl)	132 \pm 4*	187 \pm 15#	129 \pm 5.8*	115 \pm 3*	0.000
HOMA-IR	2.7 \pm 0.37*	9.7 \pm 2.1#	2.1 \pm 0.12*	1 \pm 0.3*	0.000
Cholesterol (mg/dl)	71 \pm 12.1	59 \pm 3.2	63 \pm 4.2	63 \pm 2	0.967
Triglyceride (mg/dl)	85 \pm 13*	217 \pm 18#	200 \pm 51	121 \pm 9	0.179
HDL-c (mg/dl)	24.86 \pm 1.4	29.25 \pm 1.8	29.38 \pm 2.3	28 \pm 1	0.988

Biochemical parameters were measured by autoanalyzer and hormones by ELISA kits. HOMA-IR was calculated by the formula. All data were expressed as mean \pm SEM (n=8). HCG (was fed standard chow). Con (was fed 60% fructose), Pio (was fed 60% fructose with pioglitazone-treated (10 mg/Kg)) and BIE (was fed 60% fructose with *Berberis integerrima* extract-treated (1000mg/Kg))

HCG: healthy control group, Con: control, Pio: pioglitazone, BIE: *Berberis integerrima* extract

* P-value demonstrates the difference significance between *Berberis integerrima* and control group

Significant difference with control group ($P<0.05$); # Significant difference with HCG group ($P<0.05$)




Figure 2. Effect of *Berberis integerrima* on protein level of liver PPAR γ and muscle GLUT4

The chart illustrates that the level of PPAR γ protein in pioglitazone group was significantly higher than the control group ($P < 0.0001$). Regarding the mean protein level of GLUT4 and PPAR γ , no significant difference was found between *B. integerrima* group and the control group. All data are expressed as mean \pm SEM.

HCG: healthy control group, Con: control, Pio: pioglitazone, BIE: *Berberis integerrima* extract

* Significant difference with control group ($P < 0.0001$)

Significant difference with HCG group ($P < 0.05$)

Blood glucose, triglycerides, and cholesterol

Table 2 shows that the mean blood glucose level was significantly decreased in *B. integerrima* group (115 ± 3 mg/dl) compared to the control group (187 ± 15 mg/dl) ($P < 0.0001$). However, no significant differences were observed in mean serum levels of triglycerides, cholesterol and HDL-c between *B. integerrima* and other groups. Pioglitazone did not show any effect on triglycerides in the current study (200 ± 51 mg/dl).

Serum levels of insulin and adiponectin

Comparison of *B. integerrima* group with controls, the mean level of insulin was significantly decreased (25 ± 6 pmol/l and 137 ± 34 pmol/l, respectively) ($P = 0.001$). However, the mean level of adiponectin significantly increased in *B. integerrima* as compared to the control group (3.9 ± 0.15 μ g/ml) ($P < 0.0001$). No significant difference was found in mean levels of insulin and adiponectin between *B. integerrima* and pioglitazone groups (Table 2).

Homeostasis model assessment of insulin resistance

As shown in Table 2, in *B. integerrima* treated animals (1 ± 0.3), HOMA-IR was significantly lower compared to the control group (9.7 ± 2.1) ($P < 0.0001$). Moreover, no significant difference of HOMA-IR was observed in *B. integerrima* animals in comparison with pioglitazone treated animals.

Plasma free fatty acids

Among FFA fractions, the mean serum levels of palmitoleic acid and stearic acid were significantly




Figure 3. Western blot assay of protein level of liver PPAR γ and muscle GLUT4 from HCG (was fed standard chow). Con (was fed 60% fructose), Pio (was fed 60% fructose with pioglitazone-treated (10mg/Kg)) and BIE (was fed 60% fructose with *Berberis integerrima* extract-treated (1000mg/Kg)). Immunodetection was performed using polyclonal anti- PPAR γ or anti- GLUT4 antibodies HCG: healthy control group, Con: control, Pio: pioglitazone, BIE: *Berberis integerrima* extract

higher in the *B. integerrima* group compared to the control group ($P < 0.0001$ and $P = 0.005$, respectively), while no significant difference was found in total FFAs between *B. integerrima* and control groups (Table 3).

GLUT4 and PPAR γ gene expression

Findings demonstrated that *B. integerrima* did not have any effect on PPAR γ and GLUT4 gene expression at mRNA level ($P = 1$ and $P = 0.88$, respectively). Similarly, no significant difference was observed in the mRNA level of PPAR γ and GLUT4 in pioglitazone group as compared to control group (Figure 1).

As shown in Figures 2 and 3, no significant difference was found in PPAR γ protein level between

Table 3. Effect of *Berberis integerrima* on plasma free fatty acids profiles

Parameters	Groups				P-value*
	HCG	Con	Pio	BIE	
Myristic acid (μmol/l)	1.07±0.01	1.12±0.06	1.2±0.06	1.4±0.04	0.013
Palmitic acid (μmol/l)	5.9±0.57	11.1±2.6	5.1±0.18	6.7±0.32	0.252
Palmitoleic acid (μmol/l)	1.06±0.04	1.4±0.12	1.1±0.01	2.1±0.11	0.000*
Stearic acid (μmol/l)	1.3±0.12	2.06±0.11	2.00±0.08	2.1±0.1	0.005*
Oleic acid (μmol/l)	2.2±0.21	2.9±0.22	1.7±0.08	3±0.3	0.981
Total free fatty acids (μmol/l)	12.53±1.95	22±2.7	19.44±2.8	14.1±3.13	0.132

Plasma free fatty acids profiles were measured by GC. All data were expressed as mean±SEM (n=8)

HCG (was fed standard chow), Con (was fed 60% fructose), Pio (was fed 60% fructose with pioglitazone-treated (10mg/Kg)) and BIE (was fed 60% fructose with *Berberis integerrima* extract-treated (1000 mg/Kg))

HCG: healthy control group, Con: control, Pio: pioglitazone, BIE: *Berberis integerrima* extract

* P-value demonstrates the difference between *Berberis integerrima* and control group

B. integerrima and control group. However, the level of PPAR-γ protein in pioglitazone group was significantly higher compared to the control group ($P<0.0001$). Regarding the mean protein level of GLUT4, no significant difference was observed between the *B. integerrima* and control groups (Figures 2 and 3).

Discussion

In the present study, findings demonstrated that *B. integerrima* clearly improved insulin resistance in high-fructose-fed insulin-resistant rats. We showed that *B. integerrima* extract alters body weight gain, insulin, adiponectin, blood glucose levels, and HOMA-IR. In agreement with several studies, the present findings indicated that hyperlipidemia, insulin resistance, and hyperinsulinemia states were induced after treating the animals with a high-fructose diet (3, 39, 40). Significant decreases in body weight, insulin, blood glucose, and HOMA-IR were observed after administration of *B. integerrima* in insulin-resistant rats compared to the control group. To the best of author's knowledge, there was no study on the effects of *B. integerrima* on insulin resistance until now; however, the current findings clearly indicate that *B. integerrima* improves insulin resistance.

In agreement with our previous study, *B. integerrima* like *Zataria multiflora* extract showed protective effects on glucose homeostasis and HOMA-IR (21). Decreases in insulin level along with the reduction in glucose and HOMA-IR suggest that *B. integerrima* has a direct insulin-like activity and acts as a hypoglycemic factor through improving insulin action rather than insulin secretion (44). Adipocyte accumulation plays a pivotal role in glucose homeostasis imbalance and adipose tissue inflammation (9, 10). Particularly, body weight is defined by the balance between food intake and energy expenditure (45). The present results have demonstrated that *B. integerrima* reduced body weight gain. Hence, decreases in visceral adiposity and adipocyte size could lead to improving insulin resistance.

Several studies have been put forward to explain the relationship between insulin resistance and dyslipidemia (46–48). Controversially, Ashraf *et al* have reported that administration of *B. integerrima* increased the serum levels of HDL-cholesterol and decreased triglycerides and total cholesterol (36). Further studies on the *B. integerrima* in different doses are needed to clarify the discrepancy.

Recently, it has been reported that lower production of adiponectin is directly linked to incidence of insulin resistance and metabolic syndrome (8–10). A reverse correlation has been recorded between adiponectin with adipocyte size and circulating adiponectin levels increased with weight loss (8, 49, 50). Consistent with other studies, Matsubara *et al.* findings indicated that adiponectin has a negative correlation with enlarged visceral fat, body mass index (BMI), and insulin resistance (51). Furthermore, adiponectin has been shown to come into play as major insulin-sensitizer adipokines by binding to their receptors in the liver and skeletal muscle (8, 9). TZDs increase the gene expression and plasma concentration of adiponectin and other genes involved in glucose uptake (52, 53). The serum level of adiponectin in the *B. integerrima* group was significantly higher as compared to the control group. Taken together, it could be deduced that *B. integerrima* exerts its antihyperglycemic effect, at least in part, by improving adiponectin production.

Most of the recent studies revealed that the improvement of insulin sensitivity has already been related to increased GLUT4 and PPAR-γ expression (40, 54). To clarify the molecular mechanisms involved in insulin resistance, we measured GLUT4 and PPAR-γ genes expression at the protein and mRNA levels. According to the recent studies on insulin sensitivity improvement, the activation of PPAR-γ can establish an important part of the molecular mechanism behind the adipogenesis. PPAR-γ is the most important member of the PPARs family that is involved in the adipogenesis adjustment. PPAR-γ, as a regulator of lipid and glucose metabolism, improves the insulin and glucose parameters and increases whole-body insulin sensitivity. PPAR-γ is predominantly expressed in the adipose tissue and it is the target of some anti-diabetic drugs such as pioglitazone. PPAR-γ agonists

contribute to enhancing the insulin sensitivity and glucose metabolism, and promoting the differentiation of pre-adipocytes into adipocytes. Comparing the *B. integerrima* treated group with the control group, no significant difference was found at the mRNA level between GLUT4 and PPAR- γ . Moreover, *B. integerrima* administrated group did not have any effect on protein level of GLUT4 and PPAR- γ . It can be assumed that the mechanism of decreased expression might be related to the composition of *B. integerrima*. However, PPAR- γ protein level was significantly higher in pioglitazone treated group in comparison with control group. Results derived from Sakamoto *et al.* demonstrated pioglitazone as a high-affinity selective PPAR- γ activator (55). PPAR- γ agonists ameliorate insulin resistance, reduce inflammation and enhance the differentiation of adipocytes and macrophages (56, 57). TZDs, particularly pioglitazone, have been extensively used in insulin resistance and T2DM.

Down-regulation of GLUT4 expression may enhance whole body insulin resistance and glucose imbalance (7). The GLUT4 content was lower in skeletal muscle fibers and fat tissue of type-2 diabetic patients. Besides, insulin begins insulin signaling cascade, which results in GLUT4 translocation and increased glucose uptake at the cell membrane in muscle cells. In this pathway, the impairment of any of these steps leads to the decrease of GLUT4 translocation and causes insulin resistance. Insulin decreases circulating glucose levels by suppressing hepatic glucose production and also activating GLUT4. GLUT4 increases insulin-mediated glucose uptake in muscle and adipose tissue (7, 58). In the present study, GLUT4 mRNA and protein levels were not significantly different among groups. Therefore, we speculate that the extracted *B. integerrima* contents do not increase the GLUT4 genes expression at protein and mRNA levels. However, it could improve GLUT4 translocation and glucose uptake. Moreover, no significant differences were found in GLUT4 protein and mRNA levels between the two groups. Expression and translocation of GLUT4 is increased in adipose tissue by PPAR γ (21, 57). The reason for this issue can be administration of a single dose to these groups. In striated muscle, no significant difference was found at the total GLUT4 protein between two groups, therefore, it could be supposed that translocation of GLUT4 to the cell membrane is increased after treating animals with *B. integerrima* and pioglitazone.

Many studies in animals and humans have highlighted the association of obesity with T2DM/insulin resistance (2, 9). Although the exact mechanisms have not been clearly elucidated, it could be deduced from previous studies that in most obese individuals, FFA levels are obviously too high, also acute and chronic increases in FFA levels lead to insulin resistance (18, 19). Meanwhile, this FFA

elevation causes interference in insulin signaling and function (19, 39). On the other hand, Insulin has a profound influence on the metabolic homeostasis and potently affects the metabolism of fuel molecules in adipose tissue, skeletal muscle, and the liver (58, 59). Accordingly, we analyzed the FFAs profile in high-fructose-fed insulin-resistant rats. Total plasma FFA level was not significantly different; however, palmitoleic acid and stearic acid were significantly increased in *B. integerrima* treated group in comparison with the control group. PPAR γ agonists enhance the insulin sensitivity in adipose tissue and decrease serum FFA levels (57). In the present study, no significant difference was found between pioglitazone and control groups regarding the PPAR γ gene expression, since we evaluated PPAR γ gene expression in the liver to investigate hepatic insulin resistance. This, in turn, could be suggested that further studies on PPAR γ gene expression in adipocytes are required to clarify the direct effect of PPAR γ on FFA levels. In the present study, using single dose of *B. integerrima* is one of the limitations. We could not confirm the optimal dose of *B. integerrima* because of the limited relevant investigations. Moreover, the lack of enough time and budget, and inadequate literature were some limitations of the present study.

Conclusion

The *B. integerrima* water extract, significantly improved insulin resistance in insulin-resistant rats. We demonstrated that *B. integerrima* not only increased adiponectin but also significantly reduced plasma glucose level and HOMA-IR. However, the mechanism of *B. integerrima* was independent of GLUT4 and PPAR γ . We suggest that *B. integerrima* might be a protective candidate against T2DM/insulin resistance. Therefore, further studies are needed to identify precisely which components of *B. integerrima* have the main role in its therapeutic effect.

Acknowledgment

This study was granted by Kerman University of Medical Sciences, Kerman, Iran. Authors would like to thank all the participants for help us to perform our study.

Conflict of interest

The authors declare that there is no conflict of interest.

References

- Soares FL, de Oliveira Matoso R, Teixeira LG, Menezes Z, Pereira SS, Alves AC, *et al.* Gluten-free diet reduces adiposity, inflammation and insulin resistance associated with the induction of PPAR-alpha and PPAR-gamma expression. *J Nutr Biochem* 2013; 24:1105-1111.
- Shoelson SE, Herrero L, Naaz A. Obesity, inflammation,

- and insulin resistance. *Gastroenterology* 2007; 132:2169–2180.
3. Araújo TG, de Oliveira AG, Vecina JF, Marin RM, Franco ES, Abdalla Saad MJ, *et al.* Parkinsonia aculeata (Caesalpinaceae) improves high-fat diet-induced insulin resistance in mice through the enhancement of insulin signaling and mitochondrial biogenesis. *J Ethnopharmacol* 2016; 183:95–102.
 4. Joo H, Kim CT, Kim IH, Kim Y. Anti-obesity effects of hot water extract and high hydrostatic pressure extract of garlic in rats fed a high-fat diet. *Food Chem Toxicol* 2013; 55:100–105.
 5. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, *et al.* Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. *J Clin Invest* 2003; 112:1821–1830.
 6. Koo SH, Satoh H, Herzig S, Lee CH, Hedrick S, Kulkarni R, *et al.* PGC-1 promotes insulin resistance in liver through PPAR-alpha-dependent induction of TRB-3. *Nat Med* 2004; 10:530–534.
 7. Kahn BB, Flier JS. On diabetes : insulin resistance Obesity and insulin resistance. *J Clin Invest* 2000; 106:473–481.
 8. Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. *Mol Cell Endocrinol* 2010; 314:1–16.
 9. Jung UJ, Choi MS. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. *Int J Mol Sci* 2014; 15:6184–6223.
 10. Goossens GH. The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. *Physiol Behav* 2008; 94:206–218.
 11. Kalupahana NS, Moustaid-Moussa N, Claycombe KJ. Immunity as a link between obesity and insulin resistance. *Mol Aspects Med* 2012; 33:26–34.
 12. Esfahani M, Movahedian A, Baranchi M, Goodarzi MT. Adiponectin: an adipokine with protective features against metabolic syndrome. *Iran J Basic Med Sci* 2015; 18:430–442.
 13. Caselli C. Role of adiponectin system in insulin resistance. *Mol Genet Metab* 2014; 113:155–160.
 14. Li L, Wu L, Wang C, Liu L, Zhao Y. Adiponectin modulates carnitine palmitoyltransferase-1 through AMPK signaling cascade in rat cardiomyocytes. *Regul Pept* 2007; 139:72–79.
 15. Dupont J, Chabrolle C, Ramé C, Tosca L, Coyral-Castel S. Role of the peroxisome proliferator-activated receptors, adenosine monophosphate-activated kinase, and adiponectin in the ovary. *PPAR Res* 2008; 2008:176275.
 16. Maebuchi M, Machidori M, Urade R, Ogawa T, Moriyama T. Low resistin levels in adipose tissues and serum in high-fat fed mice and genetically obese mice: Development of an ELISA system for quantification of resistin. *Arch Biochem Biophys* 2003; 416:164–170.
 17. Boden G. Obesity, insulin resistance and free fatty acids. *Curr Opin Endocrinol Diabetes Obes* 2011; 18:139–143.
 18. Capurso C, Capurso A. From excess adiposity to insulin resistance: The role of free fatty acids. *Vasc Pharmacol* 2012; 57:91–97.
 19. Cusi K, Kashyap S, Gastaldelli A, Bajaj M, Cersosimo E. Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes. *Am J Physiol Endocrinol Metab* 2007; 292:E1775–1781.
 20. Hotamisligil GS. Inflammation and metabolic disorders 1. *Nature* 2006; 444:860–867.
 21. Mohammadi A, Gholamhoseinian A, Fallah H. Zataria multiflora increases insulin sensitivity and PPARγ gene expression in high fructose fed insulin resistant rats. *Iran J Basic Med Sci* 2014; 17:263–270.
 22. Meshkani R, Adeli K. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. *Clin Biochem* 2009; 42:1331–1346.
 23. Leguisamo NM, Lehnen AM, Machado UF, Okamoto MM, Markoski MM, Pinto GH, *et al.* GLUT4 content decreases along with insulin resistance and high levels of inflammatory markers in rats with metabolic syndrome. *Cardiovasc Diabetol* 2012; 11:100.
 24. Butler M, McKay RA, Popoff IJ, Gaarde WA, Witchell D, Murray SF, *et al.* Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice. *Diabetes* 2002; 51:1028–1034.
 25. Westerblad H, Bruton JD, Katz A. Skeletal muscle: Energy metabolism, fiber types, fatigue and adaptability. *Exp Cell Res* 2010; 316:3093–3099.
 26. Kajiya T, Ho C, Wang J, Vilardi R, Kurtz TW. Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker. *J Hypertens* 2011; 29:2476–2483.
 27. Lee JY, Hashizaki H, Goto T, Sakamoto T, Takahashi N, Kawada T. Activation of peroxisome proliferator-activated receptor-alpha enhances fatty acid oxidation in human adipocytes 3332. *Biochem Biophys Res Commun* 2011; 407:818–822.
 28. Papaetis GS, Orphanidou D, Panagiotou TN. Thiazolidinediones and type 2 diabetes: from cellular targets to cardiovascular benefit. *Curr Drug Targets* 2011; 12:1498–512.
 29. Taylor C, Hobbs FDR. Type 2 diabetes, thiazolidinediones, and cardiovascular risk. *Br J Gen Pract* 2009; 59:520–524.
 30. Papaetis GS, Orphanidou D, Panagiotou TN. Thiazolidinediones and type 2 diabetes: from cellular targets to cardiovascular benefit 2553. *Curr Drug Targets* 2011; 12:1498–1512.
 31. Seymour EM, Tanone II, Urcuyo-Llanes DE, Lewis SK, Kirakosyan A, Kondoleon MG, *et al.* Blueberry intake alters skeletal muscle and adipose tissue peroxisome proliferator-activated receptor activity and reduces insulin resistance in obese rats. *J Med Food* 2011; 14:1511–1518.
 32. Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP, *et al.* Risk of bladder cancer among diabetic patients treated with pioglitazone: Interim report of a longitudinal cohort study. *Diabetes Care* 2011; 34:916–922.
 33. Ahvazi M, Akbarzadeh M, Khalighi Sigaroodi F, Kohandel A. Introduce some of the medicinal plants species with the most traditional usage in East Mazandaran. *J Med Plants* 2012; 11:164–175.
 34. Alemardan A, Asadi W, Rezaei M, Tabrizi L, Mohammadi S. Cultivation of iranian seedless barberry (*Berberis Integerrima* “bidaneh”): A medicinal shrub. *Ind Crops Prod* 2013; 50:276–287.
 35. Potdar D, Hirwani RR, Dhulap S. Phyto-chemical and pharmacological applications of *Berberis aristata*. *Fitoterapia* 2012; 83:817–830.
 36. Ashraf H, Heidari R, Nejadi V IM. Preventive effect of *Berberis Integerrima* on the serum levels of glucose and lipids in streptozotocin (STZ)-induced diabetes in rats. *J*

Fasa Univ Med Sci 2012; 2:148–155.

37. Ashraf H, Zare S. Preventive effects of aqueous extract of *Berberis integerrima* Bge. Root on liver injury induced by diabetes Mellitus (Type 1) in rats. Iran J Pharm Res 2015; 14:335–343.
38. Chang W, Chen L, Hatch GM. Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies. Biochem Cell Biol 2015; 93:479–486.
39. Mohammadi A, Gholamhosseinian A, Fallah H. Trigonella foenum-graecum water extract improves insulin sensitivity and stimulates PPAR and γ gene expression in high fructose-fed insulin-resistant rats. Adv Biomed Res 2016; 5:54.
40. Shih CC, Lin CH, Lin WL, Wu J Bin. Momordica charantia extract on insulin resistance and the skeletal muscle GLUT4 protein in fructose-fed rats. J Ethnopharmacol 2009; 123:82–90.
41. Elrashidy R, Asker M. Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy. J Cardiovasc 2012; 17:324–333.
42. Gholamhosseinian A, Falah H, SHarififar F. Anti-hyperglycemic activity of four plants extracts effective against alpha glucosidase in normal and diabetic rats. J Kerman 2009; 15:35–44.
43. Kangani C, Kelley D, DeLany J. New method for GC/FID and GC-C-IRMS analysis of plasma free fatty acid concentration and isotopic enrichment. J Chromatogr B Anal Technol Biomed Life Sci 2008; 873:95–101.
44. Abdin AA, Baalash AA, Hamooda HE. Effects of rosiglitazone and aspirin on experimental model of induced type 2 diabetes in rats: focus on insulin resistance and inflammatory markers. J Diabetes Complications 2010; 24:168–178.
45. Paradis S, Cabanac M, Marceau P, Frankham P. Body weight and satiation after duodenal switch: 2 years later. Obes Surg 2007;17:631–6.
46. Lee YS, Cha BY, Choi SS, Choi BK, Yonezawa T, Teruya T, et al. Nobiletin improves obesity and insulin resistance in high-fat diet-induced obese mice. J Nutr Biochem 2013; 24:156–162.
47. Liu X, Li G, Zhu H, Huang L, Liu Y, Ma C, et al. Beneficial effect of berberine on hepatic insulin resistance in diabetic hamsters possibly involves in SREBPs, LXRA and PPAR α transcriptional programs. Endocr J 2010; 57:881–893.
48. Tangvarasittichai S. Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J Diabetes 2015; 6:456–480.
49. Bambace C, Telesca M, Zoico E, Sepe A, Oliosio D, Rossi A, et al. Adiponectin gene expression and adipocyte diameter: A comparison between epicardial and subcutaneous adipose tissue in men. Cardiovasc Pathol 2011; 20:e153–156.
50. Skurk T, Alberti-Huber C, Herder C, Hauner H. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 2007; 92:1023–1033.
51. Matsubara M, Maruoka S, Katayose S. Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol 2002; 147:173–180.
52. Natali A, Natali A, Ferrannini E, Ferrannini E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 2006; 49:434–441.
53. Papaetis GS, Orphanidou D, Panagiotou TN. Thiazolidinediones and type 2 diabetes: from cellular targets to cardiovascular benefit. Curr Drug Targets 2011; 12:1498–1512.
54. Elmazar MM, El-Abhar HS, Schaalan MF, Farag NA. Phytol/Phytanic acid and insulin resistance: potential role of phytanic acid proven by docking simulation and modulation of biochemical alterations. PLoS One 2013; 8:e45638.
55. Sakamoto J, Kimura H, Moriyama S, Odaka H, Momose Y, Sugiyama Y, et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 2000; 278:704–711.
56. Ye JM, Tid-Ang J, Turner N, Zeng XY, Li HY, Cooney GJ, et al. PPAR δ agonists have opposing effects on insulin resistance in high fat-fed rats and mice due to different metabolic responses in muscle. Br J Pharmacol 2011; 163:556–566.
57. Derosa G, Maffioli P. Peroxisome proliferator-activated receptor- γ (PPAR- γ) agonists on glycemic control , lipid profile and cardiovascular risk. Curr Mol Pharmacol 2012; 272–281.
58. Olson AL. Insulin resistance: cross-talk between adipose tissue and skeletal muscle, through free fatty acids, liver X receptor, and peroxisome proliferator-activated receptor- α signaling. Horm Mol Biol Clin Investig 2013; 15:115–121.
59. Guo S. Insulin signaling, resistance, and the metabolic syndrome: insights from mouse models into disease mechanisms. J Endocrinol 2014; 220:T1–23.